Mineralys Therapeutics Insider Sold Shares Worth $9,088,499, According to a Recent SEC Filing-March 2024-www.financetom.com

Mineralys Therapeutics Insider Sold Shares Worth $9,088,499, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Mineralys Therapeutics Insider Sold Shares Worth $9,088,499, According to a Recent SEC Filing

Nov 14, 2025 1:08 AM

03:45 AM EST, 11/14/2025 (MT Newswires) -- Jon Congleton, Director, Chief Executive Officer, on November 11, 2025, sold 200,000 shares in Mineralys Therapeutics ( MLYS ) for $9,088,499. Following the Form 4 filing with the SEC, Congleton has control over a total of 631,305 common shares of the company, with 631,305 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1933414/000193341425000151/xslF345X05/wk-form4_1763078487.xml

Previous page： Samsonite shareholders approve US dual listing Next page： Form 8.3

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Samsonite shareholders approve US dual listing

Mar 19, 2026

SINGAPORE, March 19 (Reuters) - Samsonite ( SMSOF ) shareholders on Thursday approved a set of resolutions designed to pave the way for a U.S dual listing, as the Hong Kong-listed luggage maker seeks greater exposure to U.S. investors and improved share liquidity. The company, whose brands include Tumi and American Tourister, last month said it was seeking a listing...

Form 8.3

Mar 19, 2026

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Arrowstreet Capital, Limited Partnership (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Samsonite shareholders approve US dual listing

Mar 19, 2026

Form 8.3

Mar 19, 2026

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...